ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Defense Logistics Agency awarded contract SPE2DP26F8911 to Teva Pharmaceuticals USA, Inc. on August 12, 2026. This award is a delivery order under the primary contract SPE2DP20D0002 and is valued at 343,526.40 dollars. The scope of this agreement focuses on the procurement of Adenovirus Type 4 and Type 7 Vaccine LIV, identified by national stock number 6505016420106 and purchase request 7017847613. This federal action was processed through the Department of Defense to secure the specified medical supplies.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(2)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Logistics Agency
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
